|By PR Newswire||
|November 25, 2012 01:00 PM EST||
-- RNActive Vaccine Technology Allows Fast Production in Response to a Pandemic Scenario
-- RNActive Vaccines Are Stable at High Temperatures Which Makes Them Suitable for Easy Worldwide Supply
-- RNActive Vaccines May Become a Novel, Broadly Applicable and Easy-to-Handle Prophylactic Class of Vaccine Against Infectious Diseases
TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases. In vivo data published by CureVac and the Friedrich-Loeffler-Institute online in Nature Biotechnology show that mRNA vaccines induced balanced, long-lived and protective immunity to influenza A virus infections in various animal models. It is also shown that the production of RNActive vaccines is highly flexible. Thus, RNActive vaccines can be rapidly supplied for a variety of virus strains and subtypes identified in response to pandemic scenarios.
"The findings and results from a very fruitful collaboration with our colleagues from the renowned Friedrich-Loeffler-Institute, underscore the medical potential of mRNA beyond cancer immunotherapy and validate the capacity of our RNActive vaccines to prevent infectious diseases," said Ingmar Hoerr, Ph.D., Chief Executive Officer of CureVac. "The synthetic nature of our RNActive vaccines reduces production time dramatically and allows for sequence-matched vaccines that can be produced quickly and reliably in a scalable process. Additionally, our vaccines can be stored at room temperature, thereby avoiding the cold-chain in contrast to all other vaccines on the market and making worldwide distribution of our vaccines logistically and financially attractive."
Lothar Stitz, M.D., Head of Institute of Immunology, FLI, Greifswald, Germany, and one of the corresponding authors of the publication, said, "Our data highlight the potential and advantages of prophylactic mRNA-based vaccines and make immunization against a broad range of pathogens possible. We have a significant need for improved technologies that could be rapidly adapted to match circulating strains and allow efficient, large-scale production if necessary. In particular, we ultimately need a broadly protective vaccine against influenza. Thus, these mRNA vaccines overcome the draw-backs of many other prophylactic vaccination methods including DNA-based approaches that can have insufficient clinical efficacy or safety and may cause residual vector immunogenicity."
The authors demonstrated that the mRNA vaccine encoding full-length hemagglutinin (HA) of the influenza A/PuertoRico/8/1934 (PR8HA) strain was immunogenic and induced balanced B- and T-cell responses in mice. Influenza A viruses are classified based on the expression of a certain subtype of HA and a certain subtype of neuraminidase (NA). HA forms the basis of all licensed influenza vaccines. Furthermore, the immunized mice were protected against death and disease upon infectious challenge by an antibody-dependent mode-of-action. Moreover, the authors targeted additional influenza A virus strains by sequence-matched, HA-specific vaccines, and showed that all vaccines induced full protection against lethal infections, including H1N1pdm09 swine flu and H5N1 bird flu virus. The mRNA vaccine was immunogenic and provided long-term protection in newborn as well as in aged mice.
Additional data revealed that full protection was achieved upon single-dose immunization against influenza A/PR8 with a multi-component HA and NA mRNA vaccine. Furthermore, mRNA vaccines provided heterologous protection; vaccination with PR8 nucleoprotein (NP) mRNA led to protection against homologous PR8 (H1N1) or heterologous MB1 (H5N1) virus. Moreover, mRNA vaccines provided immunogenicity in ferrets, the animal model of choice for preclinical proof-of-concept studies in influenza research, and pigs compared to a licensed trivalent vaccine of corresponding specificity.
The publication, entitled 'Protective efficacy of in vitro synthesized, specific messenger RNA vaccines against influenza A virus infection,' was published online in Nature Biotechnology on Nov. 25.
CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. RNActive vaccines are comprised of modified and formulated mRNA with three distinct features: The mRNA vaccines are translated into the target antigens, and the formulation and modifications lead to translatability ensuring (1) strong antigen expression, (2) increased stability and (3) enhanced immune-stimulatory activity.
CureVac is developing an entirely new class of therapies based on a fundamental new understanding of the medical potential of mRNA. Using its RNA technology platform, CureVac is currently developing novel therapeutic mRNA vaccines (RNActive) for cancer and prophylactic vaccines for infectious diseases and adjuvants based on long, non-coding RNAs (RNAdjuvant®) for enhancing the immune response of other vaccines. The company has successfully completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur and In-Cell-Art on a $33.1 million project co-funded by Defense Advanced Research Projects Agency (DARPA) for the development of prophylactic vaccines in infectious diseases utilizing its RNActive technology platform. For more information, please visit: http://www.curevac.com.
Marina Bulach, Executive Assistant
T: + 49(7071)920-53-20
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
Mar. 24, 2017 04:30 AM EDT Reads: 2,466
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 24, 2017 04:15 AM EDT Reads: 1,202
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Mar. 24, 2017 04:15 AM EDT Reads: 1,109
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
Mar. 24, 2017 03:30 AM EDT Reads: 3,154
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Mar. 24, 2017 03:15 AM EDT Reads: 7,914
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, provided the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” used open source attack tools that are free and available for download by anybody. Attendees learned where to find and how to operate these tools for the purpose of testing their own IT infrastructure. The...
Mar. 24, 2017 02:15 AM EDT Reads: 7,031
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Mar. 24, 2017 01:45 AM EDT Reads: 1,231
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
Mar. 24, 2017 01:30 AM EDT Reads: 3,483
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Mar. 23, 2017 11:30 PM EDT Reads: 728
SYS-CON Events announced today that Cloud Academy will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud computing technologies. Ge...
Mar. 23, 2017 11:30 PM EDT Reads: 4,359
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
Mar. 23, 2017 10:45 PM EDT Reads: 2,392
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Mar. 23, 2017 10:15 PM EDT Reads: 3,277
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Mar. 23, 2017 10:00 PM EDT Reads: 3,432
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Mar. 23, 2017 07:15 PM EDT Reads: 4,307
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Mar. 23, 2017 06:00 PM EDT Reads: 1,337